A novel KRT5 mutation associated with generalized severe epidermolysis bullosa simplex in a 2‑year‑old Chinese boy

Introduction

Epidermolysis bullosa simplex (EBS) refers to a number of inherited disorders characterized by mechanical stress-induced blistering of the skin (1). EBS comprises three primary types: Localized [EBS-loc; Online Mendelian Inheritance in Man (OMIM) no. 131800], generalized severe (EBS-gen sev; OMIM no. 131760) and generalized intermediate (EBS-gen intermed; OMIM no. 131900) (1). The ultrastructural pathogenesis of EBS-gen sev is the collapse of keratin filaments in basal epidermal cells, resulting in basal cell cytolysis and sequent intraepidermal blister formation, which can differ from other subtypes (2–4). EBS-gen sev typically presents with characteristic features of large, generalized blisters in early infants, and small, clustered (herpetiform) blisters in childhood. In neonates and infants, EBS-gen sev is life-threatening as cutaneous lesions are typically severe, resulting in difficulties in feeding and care (5–7). Subsequent to infancy, particularly during late childhood and adulthood, the prognosis is favorable (5–7). Mutations located at the highly conserved α-helical end segments of the 1A domain of keratin 5 (KRT5) and 2B domain of KRT14, also known as helix initiation peptide (HIP) and helix termination peptide (HTP), respectively, typically result in EBS-gen sev (8,9). To date, four pathogenic mutations have been reported to be responsible for EBS-gen sev in the Chinese population, including p.Arg165Ser and p.Lys199Asn in KRT5, and p.Arg125Cys and p.Arg125His in KRT14 (10–13).

In the present study, molecular genetic tests were performed in a 2-year-old boy with suspected EBS, and a novel missense mutation c.503A>G (p.Glu168Gly) located at the N-terminal end segment of the 1A domain of KRT5 (HIP) confirmed a diagnosis of EBS-gen sev.

Materials and methods

Case

The proband was a 2-year-old boy that was referred to the Department of Dermatology of Xinhua Hospital (Shanghai, China) in October 2013. The patient had been reported to present generalized blisters throughout his body since birth (Fig. 1A-D), which were worsened by friction or trauma and were not treated. No other symptoms were observed other than blisters. At the 9-month follow-up visit a dermatological examination showed that there was no evident improvement (Fig. 1E and F). No other relevant medical history and consanguinity was reported in the patient's family. The patient was suspected to have EBS based on the clinical manifestations, and Sanger sequencing was performed to clarify the diagnosis.

Figure 1. Clinical images of the patient in the current study. (A and B) Dystrophic or absent nails and plantar hyperkeratosis present on the first visit. (C and D) Widespread herpetiform skin blistering with post-inflammatory pigmentation over the entire body. Images A-D were captured when the child was 22 months old. No scarring is present. (E and F) Cutaneous lesions developed after 9 months. Images E and F were captured when the child was 31 months old.

Subjects

The proband, his parents and 100 population-matched healthy controls (the mean age of the healthy controls was 24 years old with a range between 18 to 30 years old and a gender ratio of females/males equal to 1.0) were enrolled in the present study. Subsequent to obtaining written informed consent from the participant's mother, peripheral blood samples were collected for DNA extraction. The present study was approved by the Institutional Review Board of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.

Methods

Genomic DNA was extracted using a TIANamp Blood DNA kit (Tiangen Biotech Co., Ltd., Beijing, China). Primers flanking all coding exons and intron-exon boundaries of KRT5 and KRT14 were designed using Primer Premier version 5.0 (Premier Biosoft, Palo Alto, CA, USA; Table I). Genomic DNA samples were amplified using polymerase chain reaction (PCR). PCR was performed as follows: A denaturation step at 94°C for 5 min; 31 cycles of denaturation at 94°C for 30 sec, an annealing step for 30 sec (temperature was according to the primers of each fragment), an extension at 72°C for 1 min and an extension at 72°C for 1 min. Next, a final extension step was performed at 4°C for 5 min, and the experiment was repeated 10–20 times. The PCR products were evaluated by a 2% agarose gel electrophoresis and were further purified using an AxyPrep DNA Gel Extraction kit (Corning Life Sciences, Corning, NY, USA), according to the manufacturer's instructions. Sanger sequencing was subsequently performed using an ABI PRISM 3730 automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Sequencing results were analyzed by Geneious version 5.6.7 software (Biomatters, Ltd., Auckland, New Zealand). An identified mutation was verified in the corresponding region of the unaffected parents of the proband and 100 population-matched healthy controls. The mutation was described by comparison with the NCBI cDNA reference sequences NM_000424.3 for KRT5 and NM_000526.4 for KRT14.

Table I. List of the primers of the KRT5 and KRT14 genes.

Table I.

List of the primers of the KRT5 and KRT14 genes.

Primer name	Primer Sequence	Annealing temperature (°C)
keratin 5-E01_F	TGGGTAACAGAGCCACCTTC
keratin 5-E01_R	TTGCACAAAGCCAAAACATC	55
keratin 5-E02_F	TAGAGGGACGGAAAGAGGTG
keratin 5-E02_R	GGAGGTGTCCATGGAAGGTA	59
keratin 5-E03+4+5_F	CCCTTCCCACTGCAAAAGTA
keratin 5-E03+4+5_R	GAGCCCCATTCTTAGTGTCG	57
keratin 5-E06+7_F	AACCAGCCCCACACTATTTG
keratin 5-E06+7_R	AGCAGCTTCGCTTTATCAGC	57
keratin 5-E08_F	CGAATCATGAGGATGGGAGT
keratin 5-E08_R	GGGATGGGAAAAGTTTGGAT	55
keratin 5-E09_F	AGGGGGTCCAGTAGAGTGCT
keratin 5-E09_R	TTCTGCAATTGGCTTGGTCT	57
keratin 14-E01_F	GACAGACATGATGAGGCGGAT
keratin 14-E01_R	CTGCCTCCTGTGCTGGAAGG	65
keratin 14-E02+3_F	CCTTCCAGCACAGGAGGCAG
keratin 14-E02+3_R	CAGCGGATTGGTGTTCCTTAG	64
keratin 14-E04−8_F	TGGTGGAACTCCTGACTGTGG
keratin 14-E04−8_R	CCATGAACCCCATGACATTG	60.8

[i] F, forward; R, reverse.

The potential impact of an amino acid substitution on the structure and function of KRT5 and KRT14 proteins was predicted using the following in silico analysis tools: PolyPhen2 (http://genetics.bwh.harvard.edu/pph2), SIFT (http://sift.bii.a-star.edu.sg) and Mutation Taster (http://www.mutationtaster.org/), which automatically generated the results following input.

Results

Sequencing results

The results of the present study indicated that mutation sequencing of KRT14 was negative, whereas a novel heterozygous missense mutation, c.503C>T (p.Glu168Gly), in KRT5 was presented in the patient. This mutation was absent in the patient's unaffected parents and the 100 population-matched healthy controls (Fig. 2).

Figure 2. Sequencing results. A novel de novo heterozygous missense mutation c.503A>G (p.Glu168Gly) in the kerain 5 gene was identified by molecular analysis. The arrow indicates the site of mutation. (A) The proband, (B) his father and a (C) normal control.

Functional consequence predictions

Analysis using PolyPhen2 indicated that the mutation c.503A>G (p.Glu168Gly) was ‘probably damaging’. Furthermore, SIFT and Mutation Taster software predicted the mutation to be ‘deleterious’ and ‘disease causing’, respectively.

Discussion

The locus of the mutation in KRT5 serves an important role in the phenotype of EBS-gen sev. The majority of causal variants of EBS-gen sev in KRT5 are missense mutations that exist in the highly conserved regions of HIP and HTP (which are critical for the intermediate filament structure and integrity of the keratin cytoskeleton), and exert a dominant negative effect on the functional protein structure (2,8,9,14). Mutations in other regions are typically associated with the milder subtypes of EBS, namely EBS-loc and EBS-gen intermed (2,8,14).

The Glu168 site (codon, GAG) is located at the boundary between the head and 1A domain (HIP) (Fig. 3). To date, three relevant substitutions have been reported. More specifically, mutations c.504G>T (p.Glu168Asp) and c.504G>C (p.Glu168Asp) result in EBS-gen intermed, while c.502G>A (p.Glu168Lys) is responsible for EBS-gen sev (15–17). Phenotype severity may be explained by the fact that Glu and Asp are acidic amino acids that share a similar structure and polarity, while Lys and Gly are very different with regards to these features. Contrary to Arg125Cys and Arg125His in the Arg125 site (a CpG-rich hotspot codon) accounting for the majority of mutations in KRT14 (8,16,18), Glu477Lys located at the C-terminal end segments of the helix 2B domain (HTP) was the most common mutation identified in KRT5 (19). This was more common than the corresponding region, Glu168 (Fig. 3; 8,14,16–18).

Figure 3. Domain information of the keratin 5 gene and a number of mutations in HIP and HTP responsible for epidermolysis bullosa simplex, generalized severe. The mutation identified in the current study is highlighted red. HIP, helix initation peptide; HTP, helix termination peptide.

Dowling-Degos disease (DDD; OMIM no. 179850) or Galli-Galli disease (an acantholytic variant of DDD) are associated with haploinsufficiency of KRT5 caused by heterozygous frameshift/nonsense mutations (such as p.Met1?, p.Gln4* and p.Ile140Asnfs*39) in the head domain of KRT5 (20–22). Furthermore, p.Pro25Leu (in the head domain) and p.Gly550Alafs*77 (in the tail domain) result in a rare subtype of EBS, known as EBS with mottled pigmentation (OMIM no. 148040), suggesting that specific regions in KRT5 may be associated with melanin transportation and distribution, and malfunction of which can result in pigmentary phenotypes (20,23).

Although variable phenotypes can arise from distinct KRT5 mutations, even from an identical mutation in one pedigree (13), substitutions in the Glu168 site primarily result in the most severe subtype of EBS, which is EBS-gen sev. However, there exist exceptions (for instance, Glu168Asp results in EBS-gen intermed), suggesting that other factors, such as epigenetic alterations, interchain interactions of protein structure, modifier genes, environmental interference and ethnic background, may exert effects that result in distinct phenotypes.

In the present study, it can be suggested that Glu168Gly is the pathogenic mutation present in the proband based on the following: i) Glu168 is highly conserved among different species (analyzed by the Mutation Taster software; (www.mutationtaster.org/); ii) functional consequence predictions are deleterious; iii) other pathogenic mutations in Glu168 have been reported (Fig. 3); and iv) the variant was not present in the patient's unaffected parents and 100 healthy controls. In combination with the generalized herpetiform blistering occurring since birth and improving with age, the 2-year-old male in the present study was diagnosed with EBS-gen sev.

The patient did not evidently improve after 9 months from the first time that they appeared at the Department of Dermatology of Xinhua Hospital (Shanghai, China), and this may be attributed to the relatively long-term clinical course of EBS-gen sev, or due to insufficient general management of EBS in the infant. Furthermore, no treatment was given within these 5 months. Subsequent general therapy of EBS-gen sev in this patient should concern the prevention of skin trauma, infection control and the maintenance of good nutrition. Since a favorable lifelong prognosis of EBS-gen sev is anticipated following the high mortality rate period (within a year from birth), prenatal diagnosis and potential gene therapy will be available to the next generation in the family.

In conclusion, the current study successfully confirmed a diagnosis of EBS-gen sev by revealing a novel de novo heterozygous missense mutation c.503A>G in the HIP of KRT5, expanding the existing mutation spectrum.

Acknowledgements

The authors would like to thank all subjects for their ongoing participation in the study. The present study was supported by grants from the PhD Programs Foundation of the Ministry of Education of China (grant no. 20130073120014) and the Natural Science Foundation of Shanghai Jiaotong University School of Medicine (grant no. 13XJ10023).

References